Journal Mobile Options
Table of Contents
Vol. 12, No. 3, 2005
Issue release date: May 2005
Neuroimmunomodulation 2005;12:157–163

Human Endometrial Leukemia Inhibitory Factor and Interleukin-6: Control of Secretion by Transforming Growth Factor-β-Related Members

Perrier d’Hauterive S. · Charlet-Renard C. · Dubois M. · Berndt S. · Goffin F. · Foidart J.-M. · Geenen V.
aUniversity of Liège, Department of Medicine, Center of Immunology, Institute of Pathology CHU-B23, Liège-Sart Tilman, bUniversity of Liège, Department of Gynecology and Obstetrics, CHR-Citadelle, Liège, and cUniversity of Liège, Institute of Pathology CHU-B23, Laboratory of Tumor and Developmental Biology, Liège-Sart Tilman, Belgium

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective(s): The implantation process is closely linked to the fundamental question of the tolerance of the maternal immune system. The main objective of this study was to investigate whether different members of the transforming growth factor-β (TGF-β) superfamily could intervene in the first steps of embryo implantation by modulating the secretion of proimplantatory leukemia inhibitory factor (LIF) and in the tolerance of the fetal graft by regulating proinflammatory interleukin (IL)-6 secretion by human endometrial epithelium (EEC) in vitro. Methods: EEC were isolated from biopsies collected from 16 informed and consenting fertile women and were cultured for 72 h. Cytokine measurements (LIF and IL-6) were realized by ELISA. Results: TGF-β1 (from 10–12 to 10–8M), -β2, -β3 and activin A (10–10 and 10–8M) increased LIF secretion by EEC cultures. Inhibin B (10–10 and 10–8M) did not stimulate LIF production by human EEC. Contrastingly, TGF-β1 (from 10–12 to 10–8M), -β2, -β3 and activin A (10–10 and 10–8M) reduced IL-6 release by the same cells. Activin A at 10–8 M also significantly reduced the stimulating effect of IL-1β (10–9M) which is known to stimulate LIF production by EEC. Only the highest concentration of inhibin B (10–8M) reduced IL-6 secretion by EEC, but did not modulate IL-1β-induced stimulation of IL-6 secretion. Conclusion(s): Besides their role in the control of the process of implantation and in the induction of embryonic mesoderm, different members of the TGF-β superfamily may also contribute in the reproductive process by enhancing endometrial proimplantatory LIF secretion and reducing proinflammatory IL-6 release by EEC.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kingsley DM: The TGF-β superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994;8:133–146.
  2. Haralson MA: Transforming growth factor-β, other growth factors, and the extracellular matrix. J Lab Clin Med 1997;130:455–458.
  3. Tanaka T, Umesaki N: Cytokine regulation of apoptotic susceptibility in a human endometrial epithelial cell line. J Reprod Immunol 2000;47:105–119.
  4. Tabibzadeh S: Homeostasis of extracellular matrix by TGF-β and lefty. Front Biosci 2002;7:1231–1246.

    External Resources

  5. Lin HY, Wang HM, Li QL, Liu DL, Zhang X, Liu GY, Qian D, Zhu C: Expression of Smad2 and Smad4, transforming growth factor-β signal transducers in rat endometrium during the estrous cycle, pre-, and peri-implantation. Anim Reprod Sci 2004;80:303–316.
  6. Graycar JL, Miller DA, Arrick BA, Lyons RM, Moses HL, Derynck R: Human transforming growth factor-β3: Recombinant expression, purification, and biological activities in comparison with transforming growth factors-β1 and -β2. Mol Endocrinol 1989;3:1977–1986.
  7. Tabibzadeh S, Lessey B, Satyaswaroop PG: Temporal and site-specific expression of transforming growth factor-β4 in human endometrium. Mol Hum Reprod 1998;4:595–602.
  8. Godkin JD, Doré JJ: Transforming growth factor-β and the endometrium. Rev Reprod 1998;3:1–6.
  9. Chegini N, Zhao Y, Williams RS, Flanders KC: Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-β1 (TGF-β1), TGF-β2, TGF-β3, and TGF-β type II receptor messenger ribonucleic acid and protein and contains [125I]TGF-β1-binding sites. Endocrinology 1994;135:439–449.
  10. Casslén B, Sandberg T, Gustavsson B, Willén R, Nilbert M: Transforming growth factor-β1 in the human endometrium. Cyclic variation, increased expression by estradiol and progesterone, and regulation of plasminogen activators and plasminogen activator inhibitor-1. Biol Reprod 1998;58:1343–1350.
  11. Kauma S, Matt D, Strom S, Eierman D, Turner T: Interleukin-1β, human leukocyte antigen HLA-DRα, and transforming growth factor-β expression in endometrium, placenta, and placental membranes. Am J Obstet Gynecol 1990;163:1430–1437.
  12. Osterlund C, Fried G: TGF-β receptor types I and II and the substrate proteins Smad 2 and 3 are present in human oocytes. Mol Hum Reprod 2000;6:498–503.
  13. Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Jakowicki JA, Krajewska WM: Expression of TGF-β type I and II receptors in normal and cancerous human endometrium. Cancer Lett 2002;186:231–239.
  14. Petraglia F, Florio P, Luisi S, Gallo R, Gadducci A, Vigano P, Di Blasio AM, Genazzani AR, Vale W: Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 1998;83:1194–1200.
  15. Jones RL, Salamonsen LA, Critchley HO, Rogers PA, Affandi B, Findlay JK: Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception. Mol Hum Reprod 2000;6:1107–1117.
  16. Florio P, Severi FM, Luisi S, Ciarmela P, Calonaci G, Cobellis L, Petraglia F: Endometrial expression and secretion of activin A, but not follistatin, increase in the secretory phase of the menstrual cycle. J Soc Gynecol Investig 2003;10:237–243.
  17. Welt CK: The physiology and pathophysiology of inhibin, activin and follistatin in female reproduction. Curr Opin Obstet Gynecol 2002;14:317–323.
  18. Ni X, Luo S, Minegishi T, Peng C: Activin A in JEG-3 cells: Potential role as an autocrine regulator of steroidogenesis in humans. Biol Reprod 2000;62:1224–1230.
  19. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Köntgen F, Abbondanzo SJ: Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 1992;359:76–79.
  20. Laird SM, Tuckerman EM, Dalton CF, Dunphy BC, Li TC, Zhang X: The production of leukaemia inhibitory factor by human endometrium: Presence in uterine flushings and production by cells in culture. Hum Reprod 1997;12:569–574.
  21. Tabibzadeh S, Kong QF, Babaknia A, May LT: Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window. Hum Reprod 1995;10:2793–2799.
  22. Vandermolen DT, Gu Y: Human endometrial interleukin-6: In vivo messenger ribonucleic acid expression, in vitro protein production, and stimulation thereof by interleukin-β. Fertil Steril 1996;66:741–747.
  23. Sharkey AM, Dellow K, Blayney M, Macnamee M, Charnock-Jones S, Smith SK: Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos. Biol Reprod 1995;53:974–981.
  24. Robertson SA, Mayrhofer G, Seamark RF: Uterine epithelial cells synthesize granulocyte-macrophage colony-stimulating factor and interleukin-6 in pregnant and nonpregnant mice. Biol Reprod 1992;46:1069–1079.
  25. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Köhler G: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339–342.
  26. Cone JL, Brown DR, DeLarco JE: An improved method of purification of transforming growth factor, type β from platelets. Anal Biochem 1988;168:71–74.
  27. Noyes RW, Hertig AI, Rock I: Dating the endometrial biopsy. Fertil Steril 1950;1:3–25.

    External Resources

  28. Laird SM, Li TC, Bolton AE: The production of placental protein 14 and interleukin-6 by human endometrial cells in culture. Hum Reprod 1993;8:793–798.
  29. De Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F, Pirenne J, Gathy R, Lopez M, Dehart I, et al: Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine 1992;4:239–248.
  30. Arici A, Engin O, Attar E, Olive DL: Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium. J Clin Endocrinol Metab 1995;80:1908–1915.
  31. Delage G, Moreau JF, Taupin JL, Hambartsoumian E, Frydman R, Tartzkovsky B, Chaouat G: In vitro modulation of the production of the cytokine HILDA/LIF, secreted by human endometrial explants: Preliminary results (in French). Contracept Fertil Sex 1995;23:622–625.
  32. Laird SM, Tuckerman E, Li TC, Bolton AE: Stimulation of human endometrial epithelial cell interleukin-6 production by interleukin-1 and placental protein 14. Hum Reprod 1994;9:1339–1343.
  33. Simon C, Piquette GN, Frances A, Polan ML: Localization of interleukin-1 type I receptor and interleukin-1β in human endometrium throughout the menstrual cycle. J Clin Endocrinol Metab 1993;77:549–555.
  34. Bigonnesse F, Labelle Y, Akoum A: Triphasic expression of interleukin-1 receptor type I in human endometrium throughout the menstrual cycle of fertile women and women with unexplained infertility. Fertil Steril 2001;75:79–87.
  35. Graham CH, Lysiak JJ, McCrae KR, Lala PK: Localization of transforming growth factor-β at the human fetal-maternal interface: Role in trophoblast growth and differentiation. Biol Reprod 1992;46:561–572.
  36. Bischof P, Campana A: Molecular mediators of implantation. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:801–814.
  37. Karmakar S, Das C: Regulation of trophoblast invasion by IL-1β and TGF-β1. Am J Reprod Immunol 2002;48:210–219.
  38. Graham CH, Lala PK: Mechanisms of placental invasion of the uterus and their control. Biochem Cell Biol 1992;70:867–874.
  39. Graham CH, Connelly I, MacDougall JR, Kerbel RS, Stetler Stevenson WG, Lala PK: Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-β. Exp Cell Res 1994;214:93–99.
  40. Dunn NR, Vincent SD, Oxburgh L, Robertson EJ, Bikoff EK: Combinatorial activities of Smad2 and Smad3 regulate mesoderm formation and patterning in the mouse embryo. Development 2004;131:1717–1728.
  41. Sachdeva G, Patil V, Katkam RR, Manjramkar DD, Kholkute SD, Puri CP: Expression profiles of endometrial leukemia inhibitory factor, transforming growth factor-β2 (TGF-β2), and TGF-β2 receptor in infertile bonnet monkeys. Biol Reprod 2001;65:1–8.
  42. McLennan IS, Koishi K: Fetal and maternal transforming growth factor-β1 may combine to maintain pregnancy in mice. Biol Reprod 2004;70:1614–1618.
  43. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, de Kretser DM: Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 2001;180:155–162.
  44. Mylonas I, Jeschke U, Winkler L, Makovitzky J, Richter DU, Briese V, Friese K: Immunohistochemical expression of inhibin-α in human endometrium and the in vitro secretion of inhibin, estradiol and cortisol in cultured human endometrial glandular cells. Arch Gynecol Obstet 2003;268:142–150.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50